Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such com-pounds are contemplated for use in the treatment of diseases and disordersuch as learning, cognitive activities, and analgesia, par¬ticularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable de¬livery forms of the compounds, including intravenous formulations, are also disclosed.
